Loading...

Humacyte, Inc.

HUMANASDAQ
Healthcare
Biotechnology
$1.80
$0.05(3.15%)

Humacyte, Inc. (HUMA) Stock Overview

Explore Humacyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 73.7/100

Key Financials

Market Cap278.4M
P/E Ratio-4.77
EPS (TTM)$-0.47
ROE3.08%
Fundamental Analysis

AI Price Forecasts

1 Week$3.32
1 Month$0.36
3 Months$3.53
1 Year Target$4.70

HUMA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Humacyte, Inc. (HUMA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 54.12, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.70.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.77 and a market capitalization of 278.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;